CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Inflammatory Bowel Disease

New Data from CytoReason published in Gut outlines the role of a new technological platform approach that has revealed a new blood-based biomarker that is 94% accurate in pretreatment identification of anti-TNFα non-responders in inflammatory bowel disease (IBD), accounting for approximately 30% of patients, confirming validity of the approach.